Actemra passes muster in Japanese postmarketing evaluation
This article was originally published in Scrip
Executive Summary
The drug regulatory authority in Japan has lifted postmarketing surveillance (PMS) requirements imposed on Chugai's (Roche) therapeutic antibody Actemra (tocilizumab) as a condition of its approval in two indications.